Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7789 open-label dose escalation and expansion study in advanced or metastatic solid tumors
2022-502774-17-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, open-label trial of sabestomig in non-small cell lung cancer (NSCLC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 1 more (6 arms), sponsored by AstraZeneca. Primary endpoints: Adverse events, immune-mediated adverse events, serious adverse events, and dose-limiting toxicities, Adverse events leading to discontinuation and 2 more. Started May 2024; status: completed.
02
Drugs
sabestomig
03
Conditions
non-small cell lung cancer (NSCLC)gastric adenocarcinomagastroesophageal junction adenocarcinomaNonhematologic neoplasms
Beyond the preview
Go deeper on 2022-502774-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502774-17-00.